APA (7th ed.) Citation

Chang, S., Pan, Z., Zhang, Y., Zhang, Y., Sun, J., Guo, Y., . . . Reikvam, H. K. (2025). Potential Off‐Target Effect of Gilteritinib With Venetoclax Decreases Tumor Burden for Patients With Relapsed/Refractory Wild‐Type FLT3 Acute Myeloid Leukemia/Myelodysplastic Neoplasms. Case Reports in Hematology, 2025, 1. https://doi.org/10.1155/crh/4335095

Chicago Style (17th ed.) Citation

Chang, Shuting, Zhijuan Pan, Yiqun Zhang, Ying Zhang, Jiajia Sun, Yanru Guo, Xinlei Guo, Zhiping Guo, and Ha Kon Reikvam. "Potential Off‐Target Effect of Gilteritinib With Venetoclax Decreases Tumor Burden for Patients With Relapsed/Refractory Wild‐Type FLT3 Acute Myeloid Leukemia/Myelodysplastic Neoplasms." Case Reports in Hematology 2025 (2025): 1. https://doi.org/10.1155/crh/4335095.

MLA (9th ed.) Citation

Chang, Shuting, et al. "Potential Off‐Target Effect of Gilteritinib With Venetoclax Decreases Tumor Burden for Patients With Relapsed/Refractory Wild‐Type FLT3 Acute Myeloid Leukemia/Myelodysplastic Neoplasms." Case Reports in Hematology, vol. 2025, 2025, p. 1, https://doi.org/10.1155/crh/4335095.